熱門資訊> 正文

诺华获得英国批准Rhapsido治疗荨麻疹

2026-08-07 01:25

諾華製藥(NVS) 0

The UK's Medicines and Healthcare products Regulatory Agency has approved Novartis' (NVS) Rhapsido (remibrutinib) for chronic spontaneous urticaria.
The approval of the BTK inhibitor was based on the results of two trials in patients that failed on an antihistamine. Those on remibrutinib saw greater reductions in itch and hive symptoms compared with placebo.
Rhapsido was approved by the US FDA in 2025.

More on Novartis

Novartis: The Buy Thesis Is Back (Rating Upgrade)
Novartis AG (NVS) Q2 2026 Earnings Call Transcript
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
Novartis gains expanded indication for Pluvicto
Novartis rises as Q2 results beat on both lines

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。